SE8004580L
(sv)
*
|
1980-06-19 |
1981-12-20 |
Draco Ab |
Farmaceutisk beredning
|
SE8008524L
(sv)
*
|
1980-12-04 |
1982-06-05 |
Draco Ab |
4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
|
IT1196142B
(it)
*
|
1984-06-11 |
1988-11-10 |
Sicor Spa |
Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
|
SE8403905D0
(sv)
*
|
1984-07-30 |
1984-07-30 |
Draco Ab |
Liposomes and steroid esters
|
SE8501693D0
(sv)
*
|
1985-04-04 |
1985-04-04 |
Draco Ab |
Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
|
US5215979A
(en)
*
|
1985-12-19 |
1993-06-01 |
Aktiebolaget Draco |
16,17-acetalsubstituted pregnane 21-oic acid derivatives
|
SE8506015D0
(sv)
*
|
1985-12-19 |
1985-12-19 |
Draco Ab |
Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
|
SE8604059D0
(sv)
*
|
1986-09-25 |
1986-09-25 |
Astra Pharma Prod |
A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
|
LV5274A3
(lv)
*
|
1988-02-29 |
1993-10-10 |
Richter Gedeon Vegyeszet |
22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
|
HU203769B
(en)
*
|
1989-03-09 |
1991-09-30 |
Richter Gedeon Vegyeszet |
Process for producing new steroide derivatives and pharmaceutical compositions containing them
|
SE8903219D0
(sv)
*
|
1989-10-02 |
1989-10-02 |
Astra Ab |
Process for the manufacture of budesonide
|
US5643602A
(en)
*
|
1989-11-22 |
1997-07-01 |
Astra Aktiebolag |
Oral composition for the treatment of inflammatory bowel disease
|
SE8903914D0
(sv)
|
1989-11-22 |
1989-11-22 |
Draco Ab |
Oral composition for the treatment of inflammatory bowel diseases
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
US5888995A
(en)
*
|
1991-02-04 |
1999-03-30 |
Astra Aktiebolag |
Steroid esters
|
SE9100341D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroids
|
SE9100342D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroid esters
|
IE67345B1
(en)
*
|
1991-03-12 |
1996-03-20 |
Akzo Nv |
Low dose dry pharmaceutical preparations
|
FR2675146A1
(fr)
*
|
1991-04-10 |
1992-10-16 |
Roussel Uclaf |
Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
|
MD24C2
(ro)
*
|
1991-07-09 |
1994-05-31 |
Fabrica De Parfumerii Si Cosmetica "Viorica" |
Compoziţie de substanţe odorante
|
LT3695B
(en)
|
1991-11-18 |
1996-02-26 |
Dineika Raimundas Arnas |
Folded roof
|
CA2123909C
(fr)
*
|
1991-12-18 |
2002-10-01 |
Christer Carl Gustav Carling |
Nouvelle combinaison de formoterol et de budesonide
|
DK0675897T3
(da)
*
|
1992-12-24 |
1998-01-26 |
Rhone Poulenc Rorer Ltd |
Nye steroider
|
KR960700266A
(ko)
*
|
1993-01-08 |
1996-01-19 |
클래스 빌헬름슨 |
신규 결장- 또는 회장-특이성 스테로이드 유도체(Novel Colon-or lleum-Specific Steroid Derivatives)
|
GB9423919D0
(en)
*
|
1994-11-26 |
1995-01-11 |
Rhone Poulenc Rorer Ltd |
Chemical process
|
US6166024A
(en)
|
1995-03-30 |
2000-12-26 |
Mayo Foundation For Medical Education And Research |
Use of topical azathioprine and thioguanine to treat colorectal adenomas
|
FR2756739B1
(fr)
*
|
1996-12-05 |
2000-04-28 |
Astra Ab |
Nouvelle formulation de budesonide
|
IT1291288B1
(it)
|
1997-04-30 |
1999-01-07 |
Farmabios Srl |
Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
|
DE29717252U1
(de)
*
|
1997-09-26 |
1998-02-19 |
Dr. Falk Pharma GmbH, 79108 Freiburg |
Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
|
US6266556B1
(en)
|
1998-04-27 |
2001-07-24 |
Beth Israel Deaconess Medical Center, Inc. |
Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
|
US6667299B1
(en)
*
|
2000-03-16 |
2003-12-23 |
Hollis-Eden Pharmaceuticals, Inc. |
Pharmaceutical compositions and treatment methods
|
JP5005127B2
(ja)
|
1999-05-04 |
2012-08-22 |
ストラカン・インターナショナル・リミテッド |
アンドロゲングリコシド及びそのアンドロゲン作用活性
|
GB0009584D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Pharmaceutical compositions
|
GB0009583D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Respiratory formulations
|
GB0009613D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Pharmaceutical compositions
|
AR028948A1
(es)
*
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
US20030055026A1
(en)
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
IL144900A
(en)
|
2001-08-14 |
2013-12-31 |
Neurim Pharma 1991 |
Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
|
WO2004033478A2
(fr)
*
|
2002-10-08 |
2004-04-22 |
Sepracor Inc. |
Formes modifiees par l'acide gras des glucocorticoides
|
WO2004091596A2
(fr)
*
|
2003-04-18 |
2004-10-28 |
Pharmacia & Upjohn Company Llc |
Polytherapies
|
TWI359675B
(en)
*
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
BRPI0413330A
(pt)
*
|
2003-08-29 |
2006-10-10 |
Ranbaxy Lab Ltd |
inibidores de fosfodiesterase do tipo iv, composição farmacêutica contendo os mesmos e processo para sua preparação
|
WO2005051931A2
(fr)
*
|
2003-11-26 |
2005-06-09 |
Ranbaxy Laboratories Limited |
Inhibiteurs de la phosphodiestérase
|
EP1737861A4
(fr)
|
2004-04-09 |
2010-04-28 |
Merck Sharp & Dohme |
Inhibiteurs de l'activite d'akt
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200744612A
(en)
*
|
2005-08-26 |
2007-12-16 |
Astrazeneca Ab |
New combination
|
US7915286B2
(en)
|
2005-09-16 |
2011-03-29 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
CA2626628A1
(fr)
*
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Compositions d'inhibiteurs de la phosphodiesterase de type iv
|
BRPI0617674A2
(pt)
|
2005-10-19 |
2011-08-02 |
Ranbaxy Lab Ltd |
composições farmacêuticas e seus usos
|
JP2009512733A
(ja)
*
|
2005-11-02 |
2009-03-26 |
シコール インコーポレイティド |
シクレソニドの改良された製造法
|
AR059216A1
(es)
|
2006-01-27 |
2008-03-19 |
Sun Pharmaceutical Ind Ltd |
11b-hidroxiandrosta-4-eno-3-onas
|
US20070232578A1
(en)
*
|
2006-02-15 |
2007-10-04 |
Pierluigi Rossetto |
Crystalline forms of ciclesonide
|
ES2296516B1
(es)
*
|
2006-04-27 |
2009-04-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
JO2868B1
(en)
|
2006-08-22 |
2015-03-15 |
رانبكسي لابوراتوريز ليمتد |
Inhibitors of metabolic protein protein enzyme
|
US20100029728A1
(en)
*
|
2006-09-22 |
2010-02-04 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
JP2010504323A
(ja)
*
|
2006-09-22 |
2010-02-12 |
ランバクシー ラボラトリーズ リミテッド |
Iv型ホスホジエステラーゼの阻害物質
|
ES2302447B1
(es)
*
|
2006-10-20 |
2009-06-12 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
SI2099442T1
(sl)
|
2006-12-26 |
2015-03-31 |
Pharmacyclics, Inc. |
Postopek uporabe inhibitorjev histon deacetilaze in spremljanje biomarkerjev v kombiniranjem zdravljenju
|
PL2336120T3
(pl)
|
2007-01-10 |
2014-12-31 |
Msd Italia Srl |
Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
|
GB0702456D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
New combination
|
ES2306595B1
(es)
*
|
2007-02-09 |
2009-09-11 |
Laboratorios Almirall S.A. |
Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
|
US10201490B2
(en)
|
2007-02-14 |
2019-02-12 |
Polichem Sa |
Use of chitosans for the treatment of nail inflammatory diseases
|
EP1958639A1
(fr)
|
2007-02-14 |
2008-08-20 |
Polichem S.A. |
Utilisation de chitosanes dans le traitement de maladies inflammatoires des ongles
|
EP1958947A1
(fr)
|
2007-02-15 |
2008-08-20 |
Ranbaxy Laboratories Limited |
Inhibiteurs de la phosphodiestérase de type 4
|
DK2124944T3
(da)
*
|
2007-03-14 |
2012-04-23 |
Ranbaxy Lab Ltd |
Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
|
EP2124943A1
(fr)
*
|
2007-03-14 |
2009-12-02 |
Ranbaxy Laboratories Limited |
Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérases
|
EP2170076B1
(fr)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
|
US20090082319A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched budesonide
|
WO2009045539A2
(fr)
|
2007-10-05 |
2009-04-09 |
Nektar Therapeutics Al, Corporation |
Conjugués d'oligomères et corticostéroïdes
|
ES2320961B1
(es)
*
|
2007-11-28 |
2010-03-17 |
Laboratorios Almirall, S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
|
EP2096105A1
(fr)
*
|
2008-02-28 |
2009-09-02 |
Laboratorios Almirall, S.A. |
Dérivés de 4-(2-amino-1-hydroxyethyl)phénol en tant qu'antagonistes du récepteur adrénergique b2
|
CA2714653A1
(fr)
*
|
2008-03-13 |
2009-09-17 |
Farmabios S.P.A. |
Procede pour la preparation de derives de pregnane
|
ITMI20080645A1
(it)
|
2008-04-11 |
2009-10-12 |
Ind Chimica Srl |
Procedimento per la preparazione di budesonide
|
EP2111861A1
(fr)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions d'inhibiteurs de type IV de la phosphodiestérase
|
CN101279997B
(zh)
*
|
2008-05-29 |
2011-08-24 |
鲁南制药集团股份有限公司 |
布地奈德的一种制备方法
|
UY32297A
(es)
|
2008-12-22 |
2010-05-31 |
Almirall Sa |
Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
|
GB0900484D0
(en)
|
2009-01-13 |
2009-02-11 |
Angeletti P Ist Richerche Bio |
Therapeutic agent
|
EP2228368A1
(fr)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one
|
WO2010114780A1
(fr)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activité akt
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
TWI792140B
(zh)
|
2009-05-29 |
2023-02-11 |
美商沛爾醫療股份有限公司 |
用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
|
US8815258B2
(en)
|
2009-05-29 |
2014-08-26 |
Pearl Therapeutics, Inc. |
Compositions, methods and systems for respiratory delivery of two or more active agents
|
GB0916608D0
(en)
|
2009-09-22 |
2009-11-04 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CN106421797A
(zh)
|
2009-10-01 |
2017-02-22 |
艾戴尔医药公司 |
口服给予的皮质类固醇组合物
|
MY174452A
(en)
|
2009-10-14 |
2020-04-19 |
Schering Corp |
Substituted piperidines that increase p53 activity and the uses thereof
|
WO2011073662A1
(fr)
|
2009-12-17 |
2011-06-23 |
Astrazeneca Ab |
Association d'une benzoxazinone et d'un autre agent pour le traitement de maladies respiratoires
|
WO2011093812A2
(fr)
|
2010-01-28 |
2011-08-04 |
Mahmut Bilgic |
Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
|
JP2013518909A
(ja)
|
2010-02-08 |
2013-05-23 |
キナゲン,インク. |
アロステリックキナーゼ阻害が関係する治療方法および組成物
|
CN101863952B
(zh)
*
|
2010-04-30 |
2013-04-17 |
湖北葛店人福药业有限责任公司 |
布地奈德的制备方法
|
EP2584903B1
(fr)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
|
EP3330377A1
(fr)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
|
CN103282497B
(zh)
|
2010-08-17 |
2018-07-10 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
|
EP2608669B1
(fr)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
|
WO2012030685A2
(fr)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
|
EP2615916B1
(fr)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
CA2831730A1
(fr)
|
2011-04-21 |
2012-10-26 |
Piramal Enterprises Limited |
Forme cristalline d'un sel d'un derive de morpholinosulfonylindole et son procede de preparation
|
CA2845806C
(fr)
|
2011-09-13 |
2019-06-11 |
Pharmacyclics, Inc. |
Formulations d'un inhibiteur d'histone desacetylase en combinaison avec la bendamustine et leurs utilisations
|
EP2578570A1
(fr)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
|
EP2770987B1
(fr)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Nouveaux composés qui sont des inhibiteurs d'erk
|
WO2013109214A1
(fr)
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Procédé de préparation de formulations en poudre sèche
|
EP2641900A1
(fr)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
|
EP2844261B1
(fr)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
Compositions de petit acide nucléique interférent (sina)
|
CN103421075B
(zh)
*
|
2012-05-16 |
2017-07-28 |
上海特化医药科技有限公司 |
孕烷衍生物16,17‑缩醛(酮)的制备方法
|
US20150224197A1
(en)
|
2012-07-05 |
2015-08-13 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Inhalation compositions
|
WO2014007771A2
(fr)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Compositions d'inhalation comprenant un antagoniste du récepteur muscarinique
|
US20150165037A1
(en)
|
2012-07-05 |
2015-06-18 |
Arven llac Sanayi Ve Ticaret A.S. |
Inhalation compositions comprising corticosteroid and sorbitol
|
US10111957B2
(en)
|
2012-07-05 |
2018-10-30 |
Arven Ilac Snayi ve Ticaret A.S. |
Inhalation compositions comprising glucose anhydrous
|
WO2014031936A2
(fr)
|
2012-08-24 |
2014-02-27 |
Philip Jones |
Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
|
RU2660429C2
(ru)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Новые соединения, которые являются ингибиторами erk
|
CA2892361A1
(fr)
|
2012-11-28 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Utilisation d'un inhibiteur wee1 pour traiter un cancer caracterise par de faibles niveaux d'expression de proteines tyrosine et threonine kinases 1 (pkmyt1) associee a la membrane
|
AU2013361694B2
(en)
|
2012-12-20 |
2017-10-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
EP2951180B1
(fr)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
|
US20140275517A1
(en)
|
2013-03-15 |
2014-09-18 |
Pearl Therapeutics, Inc. |
Methods and systems for conditioning of particulate crystalline materials
|
KR20160013134A
(ko)
|
2013-05-22 |
2016-02-03 |
펄 테라퓨틱스 인코포레이티드 |
3 개 이상의 활성제의 호흡기 전달을 위한 조성물, 방법 및 시스템
|
WO2015034925A1
(fr)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Polynucléotides circulaires
|
WO2015034678A2
(fr)
|
2013-09-06 |
2015-03-12 |
Aptalis Pharmatech, Inc. |
Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
|
CA3018328A1
(fr)
|
2014-10-31 |
2016-04-30 |
Purdue Pharma |
Methodes et compositions destinees au traitement du trouble de deficit d'attention
|
US10233210B2
(en)
|
2015-01-30 |
2019-03-19 |
Coral Drugs Pvt. Ltd. |
Process for preparation of glucocorticoid steroids
|
EP3475275B1
(fr)
|
2016-06-23 |
2024-04-10 |
Merck Sharp & Dohme LLC |
5-trifluorométhyl-oxadiazoles substitués en 3-aryle et hétéroaryle en tant qu'inhibiteurs de l'histone désacétylase 6 (hdac6)
|
TWI728172B
(zh)
|
2016-08-18 |
2021-05-21 |
美商愛戴爾製藥股份有限公司 |
治療嗜伊紅性食道炎之方法
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
KR20190074310A
(ko)
|
2016-11-08 |
2019-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
스테로이드 및 이의 단백질-접합체
|
JP7364471B2
(ja)
|
2017-05-18 |
2023-10-18 |
レゲネロン ファーマシューティカルス,インコーポレーテッド |
シクロデキストリンタンパク質薬物コンジュゲート
|
MA50259A1
(fr)
|
2018-01-08 |
2021-07-29 |
Regeneron Pharma |
Stéroïdes et leurs conjugués-anticorps
|
AU2019265703A1
(en)
|
2018-05-09 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-MSR1 antibodies and methods of use thereof
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
WO2020033284A1
(fr)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de prmt5
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
JP2023507634A
(ja)
|
2019-12-17 |
2023-02-24 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Prmt5阻害剤
|
KR20240042437A
(ko)
|
2021-07-09 |
2024-04-02 |
아스트라제네카 파마수티컬스 엘피 |
에어로졸 약물 전달을 위한 조성물, 방법 및 시스템
|
CN118414148A
(zh)
|
2021-12-20 |
2024-07-30 |
阿斯利康(瑞典)有限公司 |
用于气溶胶药物递送的组合物、方法和系统
|
WO2024049931A1
(fr)
|
2022-09-02 |
2024-03-07 |
Merck Sharp & Dohme Llc |
Compositions pharmaceutiques à base d'inhibiteurs de la topoisomérase-1 dérivés de l'exatécan, et leurs utilisations
|
WO2024091437A1
(fr)
|
2022-10-25 |
2024-05-02 |
Merck Sharp & Dohme Llc |
Charges utiles de lieur adc dérivées d'exatécan, compositions pharmaceutiques et leurs utilisations
|
WO2024129628A1
(fr)
|
2022-12-14 |
2024-06-20 |
Merck Sharp & Dohme Llc |
Charges utiles-lieur d'auristatine, compositions pharmaceutiques et leurs utilisations
|